Reveal LINQ vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Reveal LINQ

by Medtronic

EchoNext

by Pathway Labs

AI Verdict

These tools are adjacent in their application of AI to cardiology but serve different diagnostic stages. Reveal LINQ is an implantable device for continuous, long-term ECG monitoring to detect arrhythmias, suitable for patients needing extended cardiac event detection. EchoNext, conversely, analyzes standard, single-point ECGs to identify hidden structural heart disease, making it a non-invasive tool for initial screening or risk assessment.

Choose Reveal LINQ if…

Choose Reveal LINQ if you need long-term, continuous ECG monitoring for up to three years to detect elusive cardiac arrhythmias like atrial fibrillation, cryptogenic stroke, or unexplained syncope. This implantable device is ideal for patients requiring extended diagnostic periods where intermittent monitoring has been insufficient. Its AI algorithms help reduce false alerts, ensuring more accurate and actionable data for diagnosis and treatment.

View Reveal LINQ →

Choose EchoNext if…

Choose EchoNext if you need a non-invasive, AI-powered screening tool to detect hidden structural heart disease, such as heart failure, valve disease, or pulmonary hypertension, from a standard 12-lead ECG. This tool is best suited for early detection in a broad patient population, potentially identifying high-risk conditions that might otherwise be missed by human interpretation alone.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Reveal LINQ	EchoNext
Pricing	Contact vendor for pricing	Starts at $600/month
Deployment	Implantable medical device with a bedside patient monitor (MyCareLink™) for data transmission and a mobile app (Reveal LINQ™ Mobile Manager) for clinicians.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext (Tool B) appears to have a broader and simpler usability profile as it analyzes standard ECGs, a routine and non-invasive test. It integrates with the OpenEvidence clinical decision support platform, making it accessible to a large number of physicians within their existing workflow. In contrast, Reveal LINQ (Tool A) is an implantable device, requiring a minimally invasive surgical procedure for insertion, which inherently makes its initial 'usability' more involved for the patient.

Clinical Value

Reveal LINQ

Reveal LINQ (Tool A) offers continuous ECG monitoring for up to three years, utilizing AI algorithms to detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope. This long-term, continuous monitoring provides a comprehensive dataset that can lead to earlier diagnosis and intervention for intermittent and often asymptomatic arrhythmias. While EchoNext (Tool B) is valuable for detecting hidden structural heart disease from standard ECGs, its role is primarily as a screening tool to identify patients who may need further imaging.

Pricing & Value

EchoNext

EchoNext (Tool B) offers transparent tiered pricing starting at $600/month, with options for different organizational sizes and an annual discount. This clear pricing structure allows healthcare providers to better assess costs. In contrast, Reveal LINQ (Tool A) requires contacting the vendor for pricing, which is typical for medical devices and often involves negotiated rates and insurance coverage, making direct cost comparison and budgeting more challenging.

Enterprise Readiness

EchoNext

EchoNext (Tool B) is deployed through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians, indicating a strong existing infrastructure for enterprise adoption and integration into clinical workflows. Pathway Labs also secured an $8.5 million seed financing round to support expansion across health systems. Reveal LINQ (Tool A), while a Medtronic product with implied enterprise support, is an implantable device with associated logistical considerations for surgical procedures and remote monitoring infrastructure.

Innovation

EchoNext

EchoNext (Tool B) represents a significant innovation by being the world's first FDA-approved AI tool to detect hidden structural heart disease from standard ECGs, a test traditionally not used for this purpose. This allows for earlier, non-invasive screening for conditions like heart failure and valve disease. While Reveal LINQ (Tool A) is a highly advanced and miniaturized implantable cardiac monitor with AI algorithms, the concept of implantable loop recorders for arrhythmia detection is more established.

Support & Docs

Reveal LINQ

Medtronic (Tool A) provides extensive support and documentation for Reveal LINQ, including patient resources, technical services, and clinical evidence. As a large, established medical device company, Medtronic has a robust support infrastructure. While EchoNext (Tool B) is a newer offering, specific details about its ongoing support and documentation for end-users beyond its integration with OpenEvidence are not as readily available in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Reveal LINQ	EchoNext
Name	Reveal LINQ	EchoNext
Company	Medtronic	Pathway Labs
Description	Tiny, implantable cardiac monitor that continuously records ECG for up to three years, utilizing AccuRhythmu2122 AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	World's smallest insertable cardiac monitor (1.2 mL); Continuous ECG monitoring for up to three years; AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause); Automatic and patient-activated event recording; MRI Conditional (1.5T and 3T) with no post-insertion waiting; Minimally invasive, simplified insertion procedure; Wireless data transmission to CareLinku2122 network via MyCareLinku2122 Patient Monitor; Reveal LINQu2122 Mobile Manager app for clinician device management.	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support.

Videos

Demos, reviews, and walkthroughs featuring Reveal LINQ and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools fit into my existing clinical workflow, and what is the learning curve for my team?

Reveal LINQ involves a minimally invasive implantation procedure, and its mobile manager app allows for patient setup up to 7 days prior to insertion, streamlining the process. The data is then transmitted wirelessly to the CareLink network via a bedside patient monitor. EchoNext, on the other hand, integrates directly with the OpenEvidence clinical decision support platform, which is used by many clinicians, meaning its screening output is available within a tool physicians may already be using, potentially reducing the learning curve for integration into existing diagnostic pathways.

What is the depth of EHR integration for each tool, and how will data be accessed and managed?

Reveal LINQ transmits continuous ECG data to the CareLink network, and the Reveal LINQ Mobile Manager app facilitates device management and CareLink network pre-enrollment. While Medtronic emphasizes protection of patient health data, specific details on direct EHR integration depth beyond the CareLink network are not provided. EchoNext is available through the OpenEvidence platform, which aims to place its screening output directly into tools physicians already use, suggesting a more integrated approach to data access within existing clinical decision support systems.

How do the accuracy and sensitivity of the AI algorithms compare for detecting relevant cardiac conditions?

Reveal LINQ utilizes AccuRhythmu2122 AI algorithms to continuously monitor ECG for up to three years, significantly reducing false alerts for AF and pause while preserving sensitivity. EchoNext, an AI tool for analyzing standard ECGs, has demonstrated high diagnostic accuracy for structural heart disease, outperforming cardiologists in studies, even those assisted by AI. It was trained on over 700,000 paired ECGs and echocardiograms and validated across numerous hospitals.

Which cardiac specialties are these tools best suited for, and what specific clinical problems do they address?

Reveal LINQ is primarily for cardiology and neurology, focusing on continuous ECG monitoring for up to three years to detect and diagnose cardiac arrhythmias like atrial fibrillation, cryptogenic stroke, and unexplained syncope. EchoNext is suitable for cardiology, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, acting as a screening tool to identify patients who should proceed to an echocardiogram.

What kind of support and resources are available for physicians and their teams during implementation and ongoing use?

Medtronic offers technical and patient services for Reveal LINQ. The Reveal LINQ Mobile Manager app includes guided workflow animations and integrated patient education to support usage. For EchoNext, its deployment through the OpenEvidence platform suggests that support may be integrated within that existing system, and Pathway Labs has secured funding to expand deployment and grow its clinical and commercial teams, which could indicate robust support for health systems.

What are the audit trail features for each tool, and how can I review the AI's decision-making process?

While Reveal LINQ transmits data to the CareLink network for review by clinic staff, specific audit trail features for the AI's decision-making process are not detailed, though it does generate event, summary, and full reports. For EchoNext, the information provided does not explicitly detail audit trail features or how to review the AI's decision-making process, beyond its ability to identify patterns a human may miss.

Are there any considerations for rolling out these tools across multiple sites or a large health system?

For Reveal LINQ, the miniaturized device and simplified insertion procedure, which can be performed outside a cardiac department, may facilitate multi-site rollout. The mobile manager app also allows for streamlined patient setup. EchoNext is designed for broad access, from major hospitals to community practices, and its partnership with OpenEvidence aims for deployment across health systems at a national scale, suggesting considerations for multi-site implementation are a focus.